Assessment of Ibicella lutea for antibacterial agent front Staphylococcus aureus

• Autor(a) principal: Volcão, Lisiane Martins
• Data de Publicação: 2016
• Outros Autores: Coelho, Tatiane Silveira, Vàsquez, Alváro, Cerdeiras, Maria Pia, Silva, Pedro Eduardo Almeida da, Júnior, Flávio Manoel Rodrigues da Silva, Ramos, Daniela Fernandes
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista de Epidemiologia e Controle de Infecção
• Texto Completo: https://online.unisc.br/seer/index.php/epidemiologia/article/view/8200

Justificative and Objectives: the study aimed the assessment of the antibacterial activity of crude extracts and fractions of Ibicella lutea, front Staphylococcus aureus, thecombination of these compounds and cytotoxic activity. Methods: was used for antibacterial activity the Microdilution Test Broth, and performed the Checkerboard Test. The extracts showed antibacterial activity were submitted to the citotoxicity test, with macrophages cell and determination of the Selectivity Index (SI). Results: The acetate etila fraction (AcOE) was better antimicrobial activity (6.25 µg/mL) compared with the others extracts and fractions used, however none of the compounds showed bactericidal activity in concentrations employed. In present study, we can be observed an additive activity between AcOE and methanolic (MeOH) fractions, and indifferent interaction between crude extracts. According to citotoxicity test, the extract which led to a higher survival rate of macrophage cells was the fraction AcOE (IC50%=30.35 µg/mL). However, when the calculated SI no satisfactory results (SI < 10) to any of the extracts was observed. Conclusions: in the present study we can observe an antimicrobial activity of the fractions AcOE and MeOH to S. aureus, as well as an additive this potential when the fractions are combined, providing support from isolation and characterization of yours active components. Despite the extracts did not showed a satisfactory SI, new toxicity studies should be performed to establish the potential use of safety with the products derived from I. lutea, such as drugs for topical and biocide products.